● Established and directed Live Attenuated Vaccine Design Platforms for Enterobacteriaceae strains, resulting in patent applications●Led the development of analytical assays to enhance immunogenic antigen expression and monitor product quality, resulting in improved product performance and deeper insights●Developed stable challenge animal models and managed immunogenicity studies to select optimal vaccine candidates and conduct proof of concept studies● Developed a clear understanding of project content and maintained relevant knowledge throughout the project life cycle● Managed the due diligence and expert review of the Calls for Proposals and developed a good understanding of the project subject● Collaborated with the Regulatory Director and Subject Matter Experts in formulating the Project Development Plan and implementing the derisking strategies to enhance the safety and stability of live Attenuated Vaccines in Alignment with EMA, FDA, and USDA regulatory policies● Established a strong working relationship with the team and across all parts of the organization ● Identified and developed roles for project team members and helped individual contributors to be successful in these roles● Managed potential threats by performing comprehensive risk and GAP analysis throughout the project lifecycle, including identifying, assessing, prioritizing, and mitigating risks to ensure project success.● Actively contributed to portfolio review and analysis, working closely with colleagues across the executive team, SMEs, and Scientific Advisory Committee, contributing to continuous improvement through leveraging lessons learned● Defined project deliverables, monitored status of tasks, and enforced deadlines● Delivers status reports to stakeholders for budgeting and planning proposes●Prepared and reviewed documents related to product development, protocols, study reports, work plans, patents, and regulatory submissions.

● Led coordination efforts across 5 interdisciplinary teams comprising over 30 scientists from McGill University, UdeM, and the Montreal Neurological Institute-Hospital to advance research in host-pathogen interactions.● Directed the oversight of ASAP projects, ensuring alignment with strategic objectives and facilitating collaborative project planning with team leaders.● Spearheaded the development of innovative animal models to elucidate the mechanisms underlying intestinal inflammation and Parkinson’s disease, resulting in groundbreaking insights into disease progression.● Pioneered the establishment of a novel mouse model for Adherent-invasive E. coli infection, leading to the identification of motor dysfunction as a consequence of bacterial colonization.● Innovated the fecal microbiota transfer model to investigate the role of the microbiome in disease pathology, contributing to a deeper understanding of microbial dynamics in health and disease.● Contributed technical expertise to multiple projects focused on bacterial pathogenesis, including studies on Enterohemorrhagic E. coli (EHEC), Citrobacter, Adherent-invasive E. coli (AIEC), and Helicobacter pylori.● Engineered site-specific mutations in E. coli and Citrobacter rodentium, enhancing our ability to study virulence factors and host responses.● Demonstrated proficiency in cell biology techniques, including isolation and culture of cells from animal samples, facilitating the investigation of host-pathogen interactions at the cellular level.● Developed and executed laboratory work plans and schedules for self and team, leveraging project milestones and performance standards to ensure timely and successful project completion.● Mentored and supervised undergraduate and junior graduate students, fostering their growth and development in research and laboratory practices.

Armand-Frappier Conference is intended for graduate students and postdoctoral fellows working in the fields of biological sciences, health, environment, microbiology, virology, etc. The conference is held in French mainly, the majority of participants come from Quebec universities.

• I pursued my Ph.D. studies in the laboratory of Charles M. Dozois at INRS-Centre Armand-Frappier Santé Biotechnologie. My project focused on characterizing the role of unknown function proteins and non-coding small RNAs in the virulence of pathogenic Escherichia coli.• Designed and performed experiments, data interpretation, and analyzing results as outlined in grants • Demonstrated the ability to contribute to various collaborative projects from all relevant functional areas (8 peer-reviewed research papers)• Having maintained a strong reputation within the scientific community and using this reputation to build strategic relationships to facilitate collaboration, research agreements, and outsourcing• Expertise in bacteriology, molecular and cellular biology, biochemistry, and proteomics Mutagenesis (lambda red system & allelic exchange), cell fractionation, Site-Directed Mutagenesis, cloning & genome engineering, random mutagenesis, and conjugation  RNA sequencing and Transposon sequencing, data processing, and validation Protein expression, purification of proteins Gel Based approach (SDS PAGE, Native PAGE, 2DE) and protein crystallization (basics) Practical expertise in molecular biology techniques such as qRT-PCR, Western Blot, ELISA, protein extraction, DNA, RNA and protein manipulation Cell culture: cell isolation and culture from human (human primary cells), animal samples & cell lines  Animal experimentation (mouse, chicken, turkey, hamster, and zebrafish) • Worked on a series of projects related to the characterization of new autotransporters, new RTX toxin in Avian Pathogenic E. coli, and the role of non-coding small RNAs in the virulence of Salmonella• Excellent written and oral communication skills as demonstrated by peer-reviewed publications and presentations

Représentant de L'INRS Institut Armand-Frappier Santé Biotechnologie lors de divers événements spéciaux et d'activités de recrutement.

Responsable de communication et des affaires étrangères du Congres Armand Frappier 2019

Project: Development and optimization of a new labeling method of the cell envelope proteins in lipopolysaccharides diderm bacteriaPrinciple Investigator: Dr. Mickael Desvaux• Development and optimization of a new labeling technique of the cell envelope proteins in lipopolysaccharides diderm bacteria (Biotinylation)

Conducted finished pharmaceutical product control to ensure compliance with quality standards.Monitored the quality of raw materials to maintain high manufacturing standards.Managed strains maintenance and inventory, ensuring the accuracy and availability of microbial strains.Adhered to Good Manufacturing Practices (GMP), , ensuring all procedures met industry regulations.

Conducted biomedical analyses and tests to support patient diagnoses.Maintained laboratory equipment and ensured compliance with safety and quality standards.Prepared samples and reagents with precision to facilitate laboratory procedures.Recorded and analyzed data accurately to contribute to the reporting of test results.

The research subject of my internship at the Biotechnology Laboratory and Microbiology in Algeria concerns the treatment of infectious diseases by Herbal Medicine. This training period has allowed me to use and enhance my knowledge in biochemistry, microbiology, and molecular biology and work on a serious health problem. I aim to use it further in agri-food and in environmental problems.